Published Technical Disclosure Archive

Targeted Bio-Orthogonal Prodrug Activation

Publication ID: 24-11857636_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Targeted Bio-Orthogonal Prodrug Activation,” Published Technical Disclosure No. 24-11857636_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857636_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,636.

Summary of the Inventive Concept

The invention relates to an improved method for targeted activation of prodrugs using bio-orthogonal chemical reactions, enhancing specificity, safety, and efficacy.

Background and Problem Solved

The original patent disclosed bio-orthogonal drug activation methods, but limitations included lack of targeting specificity, potential off-target effects, and inefficient activation. The new inventive concept addresses these limitations by introducing targeted delivery and activation mechanisms.

Detailed Description of the Inventive Concept

The new concept comprises a trans-cyclooctene derivative and a compatible diene, wherein the diene is conjugated to a targeting moiety or encapsulated in a nanoparticle, ensuring specific site activation. The bio-orthogonal chemical reaction is triggered by enzymatic activity or targeted delivery, enhancing efficiency and reducing off-target effects.

Novelty and Inventive Step

The new claims introduce the concept of targeted delivery and activation of prodrugs using bio-orthogonal chemical reactions, which is not obvious from the original patent. The use of trans-cyclooctene derivatives, compatible dienes, and targeting moieties or nanoparticles provides a novel and non-obvious solution to the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments include using different targeting moieties or nanoparticles, varying the structure of the trans-cyclooctene derivative and compatible diene, and exploring different enzymatic triggers for the bio-orthogonal reaction.

Potential Commercial Applications and Market

The targeted bio-orthogonal prodrug activation concept has potential applications in cancer therapy, autoimmune disease treatment, and other areas where targeted drug delivery is crucial. The market for targeted therapies is growing, and this invention offers a competitive advantage in terms of specificity, safety, and efficacy.

CPC Classifications

SectionClassGroup
A A61 A61K47/6803
A A61 A61K31/435
A A61 A61K31/444
A A61 A61K31/704
A A61 A61K38/05
A A61 A61K39/3955
A A61 A61K39/39558
A A61 A61K47/22
A A61 A61K47/545
A A61 A61K47/555
A A61 A61K47/558
A A61 A61K47/6897
B B82 B82Y5/00
C C07 C07C33/16
C C07 C07D237/26
C C07 C07D257/08
Y Y02 Y02A50/30

Field of Art

Pharmaceutical chemistry, drug delivery systems, bio-orthogonal chemistry, with a focus on targeted prodrug activation and controlled drug release mechanisms

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in pharmaceutical chemistry or chemical biology, familiar with organic synthesis, drug delivery strategies, and bio-orthogonal chemical reactions, with expertise in designing targeted drug activation systems

Obviousness Rationale

A person of ordinary skill would recognize that the PTD's targeted delivery and bio-orthogonal activation methods are logical extensions of the source patent's prodrug activation concept. The proposed variations represent predictable refinements using known chemical strategies for improving drug specificity and reducing off-target effects. The technical modifications involve standard design choices in drug delivery that would be apparent to a skilled practitioner seeking to optimize the original bio-orthogonal drug activation approach.

Obvious Combinations & Variations

Source Patent Element
Prodrug activation using bio-orthogonal chemical reactions
PTD Variation
Adding targeted delivery via nanoparticle encapsulation and specific enzymatic triggers
Obviousness Reasoning
Targeted drug delivery is a well-established technique in pharmaceutical chemistry, and combining nanoparticle systems with bio-orthogonal reactions represents a predictable optimization of the original prodrug activation method
Source Patent Element
Chemical compound with specific structural modifications for drug activation
PTD Variation
Introducing trans-cyclooctene derivatives and compatible dienes with targeting moieties
Obviousness Reasoning
Modifying molecular structures to enhance drug targeting is a routine strategy in medicinal chemistry, and the proposed variations represent known approaches to improving drug specificity
Source Patent Element
Bio-orthogonal chemical reaction mechanism
PTD Variation
Implementing retro Diels-Alder adduct formation as a monitoring and activation strategy
Obviousness Reasoning
Using well-known organic chemistry reaction mechanisms to track and trigger drug activation is a standard approach that would be obvious to a skilled practitioner
Source Patent Element
Prodrug inactivation and site-specific activation
PTD Variation
Expanding activation mechanisms to include enzymatic triggers and targeted delivery systems
Obviousness Reasoning
Exploring alternative activation mechanisms is a predictable approach in drug delivery research, representing incremental improvements within the known technological landscape
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857636 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations in targeted prodrug activation obvious and anticipated. The proposed methods represent predictable extensions of existing bio-orthogonal drug activation strategies, utilizing known chemical techniques and delivery mechanisms that would be readily apparent to a skilled practitioner in pharmaceutical chemistry and drug delivery systems.

Original Patent Information

Patent NumberUS 11,857,636
TitleBio-orthogonal drug activation
Assignee(s)Tagworks Pharmaceuticals B.V.